1. TIME TO NEXT TREATMENT IN PATIENTS WITH PREVIOUSLY TREATED CUTANEOUS T‐CELL LYMPHOMA (CTCL) RECEIVING MOGAMULIZUMAB OR VORINOSTAT: A POST‐HOC ANALYSIS OF THE MAVORIC STUDY. (12th June 2019) Authors: Kim, Y.H.; Ortiz‐Romero, P.L.; Pro, B.; Sokol, L.; Scarisbrick, J.; Musiek, A.; Vermeer, M.; Dummer, R.; Halwani, A.; Fierro, M.; Moriya, J.; Leoni, M.; Bagot, M. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 285 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. P1172: DUVELISIB IN PATIENTS WITH RELAPSED/REFRACTORY PERIPHERAL T-CELL LYMPHOMA FROM THE PHASE 2 PRIMO TRIAL: UPDATED EXPANSION PHASE ANALYSIS. (23rd June 2022) Authors: Zinzani, P. L.; Zain, J.; Mead, M.; Casulo, C.; Jacobsen, E. D.; Gritti, G.; Pinter-Brown, L.; Isutzu, K.; Cohan, D.; Daugherty, M.; Brammer, J. E.; Mehta-Shah, N.; Pro, B.; Horwitz, S. M. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 1058 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. PO-1285: Gender disparity among United States academic oncology program leadership. (November 2020) Authors: Chowdhary, M.; Chowdhary, A.; Royce, T.; Patel, K.; Chhabra, A.; Jain, S.; Knoll, M.; Vapiwala, N.; Pro, B.; Marwaha, G. Journal: Radiotherapy and oncology Issue: Volume 152(2020)Supplement 1 Page Start: S677 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. GSK‐3ß INHIBITOR, 9‐ING‐41 REDUCES CELL VIABILITY AND HALTS PROLIFERATION OF B‐CELL LYMPHOMA. (June 2017) Authors: Karmali, R.; Chukkapalli, V.; Pro, B.; Borgia, J.A.; Mazar, A.; Ugolkov, A.; Giles, F.J. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 400 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗